Showing 9011-9020 of 19239 results for "".
- Interim IIT Data Explore Sculptra, Restylane for Menopause, Weight Loss–Related Aesthetic Changeshttps://reachmd.com/news/interim-iit-data-explore-sculptra-restylane-for-menopause-weight-lossrelated-aesthetic-changes/2486595/Interim findings from 2 ongoing investigator-initiated trials supported by Galderma suggest potential roles for Sculptra and the Restylane portfolio in treating aesthetic changes associated with menopause and medication-driven weight loss. In one interim analysis led by Sabrina Fabi, MD, 2
- Ucla Listing Details Phase 2 Ianalumab Study In DcSSchttps://reachmd.com/news/ucla-listing-details-phase-2-ianalumab-study-in-dcssc/2486578/Key Takeaways: The listing describes an actively recruiting phase 2 placebo-controlled study of subcutaneous ianalumab in diffuse cutaneous systemic sclerosis. Enrollment is limited by protocol-defined diagnosis, age, disease-duration, and baseline ski
- Central Pathology Review Finds Discordance In LNG IUD Trialhttps://reachmd.com/news/central-pathology-review-finds-discordance-in-lng-iud-trial/2486579/Key Takeaways: Interobserver agreement was reported at baseline and at both post-treatment timepoints. Discordance was reported more often in site-labeled hyperplasia than adenocarcinoma, and discordant cases were frequently upgraded on central review.
- Ketamine Trial Finds No Recovery Benefit, Higher ICU Transferhttps://reachmd.com/news/ketamine-trial-finds-no-recovery-benefit-higher-icu-transfer/2486580/Key Takeaways: Ketamine in major abdominal ERAS care was reported not to reduce hospital length of stay or opioid use versus placebo. In this trial, ketamine was associated with lower odds of meeting early discharge milestones and higher odds of ICU tr
- Study Links Vitiligo to Higher Autoimmune and Infection Burden in US Cohorthttps://reachmd.com/news/vitiligo-linked-to-higher-autoimmune-and-infection-burden-in-us-cohort/2486572/New data from a large retrospective study suggested patients with vitiligo experience higher rates of several comorbidities and safety events compared with matched controls. Investigators analyzed Optum Market Clarity EHR dat
- ELEVATE-IPF: New Findings on Deupirfenidonehttps://reachmd.com/news/elevate-ipf-deupirfenidone/2486553/Key Takeaways ELEVATE-IPF randomized patients to deupirfenidone 550 mg, deupirfenidone 825 mg, pirfenidone 801 mg, or placebo. Less FVC decline was reported for combined deupirfenidone versus placebo, and a separate frequentist analysis also reported l
- Home-Based Liver Frailty Intervention Shows Feasibility in Pilot Studyhttps://reachmd.com/news/home-based-liver-frailty-intervention-feasibility/2486555/Key Takeaways A home-based liver frailty intervention using remote monitoring with home equipment and app-based support was reported to be feasible. Adherence was partial, but retention remained high and remote frailty assessment was completed during f
- Navigated TMS Trial Reports PTSD Symptom Improvementhttps://reachmd.com/news/navigated-tms-ptsd-symptom-improve/2486556/Key Takeaways Adjunctive navigated TMS was associated with greater reported PTSD symptom improvement than sham in this randomized trial population. Improvement was reported at one month, and group differences were also reported at three months. </
- First Patient Enrolled in IMPROVE-PAH Phase 3 Studyhttps://reachmd.com/news/first-patient-enrolled-in-improve-pah-phase-3-study/2486538/Key takeaways: First patient enrolled in the global, adaptive, two-part Phase 3 IMPROVE-PAH trial of IKT-001 in PAH Part A primary endpoint: change in pulmonary vascular resistance at Week 24; Part B: change in 6-minute walk distance at Week 24
- First Patient Dosed in OYE Therapeutics IV Caffeine 505(b)(2) Bridging Studyhttps://reachmd.com/news/first-patient-dosed-in-oye-therapeutics-iv-caffeine-505b2-bridging-study/2486542/Key points: First patient dosed in a 505(b)(2) bridging study of OYE-101 OYE-101 is an intravenous caffeine formulation designed to accelerate recovery from anesthesia and deep sedation Study will generate human data to support a future 505(b)